Gilead Sciences (GILD) Set to Announce Quarterly Earnings on Thursday

Gilead Sciences (NASDAQ:GILD) will be issuing its quarterly earnings data after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $1.56 per share for the quarter. Gilead Sciences has set its FY24 guidance at $6.85-7.25 EPS and its FY 2024 guidance at 6.850-7.250 EPS.Parties interested in listening to the company’s conference call can do so using this link.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.67 EPS. On average, analysts expect Gilead Sciences to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Gilead Sciences Stock Up 0.1 %

Gilead Sciences stock opened at $67.03 on Wednesday. The firm has a market cap of $83.46 billion, a price-to-earnings ratio of 14.90, a PEG ratio of 0.92 and a beta of 0.19. The stock has a fifty day simple moving average of $71.68 and a two-hundred day simple moving average of $76.46. Gilead Sciences has a 12 month low of $65.90 and a 12 month high of $87.86. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.77 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.59%. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on GILD shares. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Barclays reduced their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Mizuho dropped their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Finally, StockNews.com downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $84.71.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.